Theravance Biopharma Inc reports results for the quarter ended in March - Earnings Summary

Theravance Biopharma

08/05/2023 23:32

* Theravance Biopharma Inc  TBPH.OQ  reported a quarterly
adjusted
loss of 35 cents​​ per share for the quarter ended in March. The
mean expectation of three analysts for the quarter was for a
loss of 25 cents per share.
    * Revenue fell 21.1% to $10.42 million from a year ago;
analysts
expected $13.71 million. 
    * Theravance Biopharma Inc's reported EPS for the quarter
was a
loss of 35 cents​.
    * The mean earnings estimate of analysts had fallen by
about 11.7%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Theravance Biopharma Inc shares had risen by 4.4% this
quarter and gained 1.0% so far this year.
    * The company reported a quarterly loss of $22.09 million.
    * Wall Street's median 12-month price target for Theravance
Biopharma Inc is $14.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
8 at 10:32 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.25          -0.35          Missed
 Dec. 31 2022      -0.17          -0.15          Beat
 Sep. 30 2022      -0.18          -0.21          Missed
 Jun. 30 2022      0.11           -0.09          Missed